Milestone Pharmaceuticals (MIST) reaches agreement with Alta Advisers

Key Summary: On November 9, 2023, Alta Advisers (5%) expressed concern to the Board about potential non-value maximizing funding options for Etripamil. On July 14, 2024, they entered a Cooperation Agreement, leading the company to expand its Board and appoint Stuart M. Duty and Andrew R. Saik as Initial New Directors until the 2024 Annual Meeting.

M.Cap:…